OBJECTIVES: To examine N-terminal pro-brain natriuretic peptide (NT-proBNP) variability in plasma and urine samples of patients with stable heart failure (HF) during a 24-month follow-up. DESIGN: Prospective study. SETTING: Teaching hospital based study. PATIENTS: 74 clinically and functionally stable patients (NYHA class 2+/-0.5) out of 114 patients diagnosed with HF were followed up, and NT-proBNP plasma and urine levels were measured at baseline, 12 and 24 months. RESULTS: Significant differences in mean urinary levels (p<0.01) were found during follow-up, but no changes were found in plasma. Bland-Altman plots showed few variations in plasma percentages in the three intervals (stage I-basal; stage II-stage I; stage II-basal) with a coefficient of reproducibility (CR) of 22%, 21% and 25%, respectively. Changes in NT-proBNP urinary levels had a CR of 7.1%, 6.8% and 9.4% at the three intervals, respectively. A good correlation was found between plasma and urinary levels of NT-proBNP (p<0.001) and between the different NT-proBNP plasma (p<0.001) and urine measurements (p<0.001). CONCLUSIONS: NT-proBNP plasma and urine levels show good stability in a 24-month follow-up of patients with stable heart failure. Thus, assessment of urinary and plasma NT-proBNP concentrations may be a useful tool for monitoring patients with HF during follow-up. The results suggest that variations in peptide concentrations exceeding 22% in plasma and 7% in urine in a 12-month follow-up and 25% and 9% in a 24-month follow-up may indicate pathophysiological changes.
OBJECTIVES: To examine N-terminal pro-brain natriuretic peptide (NT-proBNP) variability in plasma and urine samples of patients with stable heart failure (HF) during a 24-month follow-up. DESIGN: Prospective study. SETTING: Teaching hospital based study. PATIENTS: 74 clinically and functionally stable patients (NYHA class 2+/-0.5) out of 114 patients diagnosed with HF were followed up, and NT-proBNP plasma and urine levels were measured at baseline, 12 and 24 months. RESULTS: Significant differences in mean urinary levels (p<0.01) were found during follow-up, but no changes were found in plasma. Bland-Altman plots showed few variations in plasma percentages in the three intervals (stage I-basal; stage II-stage I; stage II-basal) with a coefficient of reproducibility (CR) of 22%, 21% and 25%, respectively. Changes in NT-proBNP urinary levels had a CR of 7.1%, 6.8% and 9.4% at the three intervals, respectively. A good correlation was found between plasma and urinary levels of NT-proBNP (p<0.001) and between the different NT-proBNP plasma (p<0.001) and urine measurements (p<0.001). CONCLUSIONS:NT-proBNP plasma and urine levels show good stability in a 24-month follow-up of patients with stable heart failure. Thus, assessment of urinary and plasma NT-proBNP concentrations may be a useful tool for monitoring patients with HF during follow-up. The results suggest that variations in peptide concentrations exceeding 22% in plasma and 7% in urine in a 12-month follow-up and 25% and 9% in a 24-month follow-up may indicate pathophysiological changes.
Authors: T Tsutamoto; A Wada; K Maeda; N Mabuchi; M Hayashi; T Tsutsui; M Ohnishi; M Sawaki; M Fujii; T Matsumoto; T Matsui; M Kinoshita Journal: J Am Coll Cardiol Date: 2001-04 Impact factor: 24.094
Authors: L Katherine Morrison; Alex Harrison; Padma Krishnaswamy; Radmila Kazanegra; Paul Clopton; Alan Maisel Journal: J Am Coll Cardiol Date: 2002-01-16 Impact factor: 24.094
Authors: Margaret M Redfield; Richard J Rodeheffer; Steven J Jacobsen; Douglas W Mahoney; Kent R Bailey; John C Burnett Journal: J Am Coll Cardiol Date: 2002-09-04 Impact factor: 24.094
Authors: Stefanie Reynen; Michael Schlossbauer; Ute Hubauer; Julian Hupf; Arno Mohr; Evelyn Orso; Markus Zimmermann; Andreas Luchner; Lars S Maier; Stefan Wallner; Carsten G Jungbauer Journal: ESC Heart Fail Date: 2021-04-06
Authors: Esther Roselló-Lletí; Jose R Calabuig; Pedro Morillas; Raquel Cortés; Luis Martínez-Dolz; Luis Almenar; Jose R González-Juanatey; Catheline Lauwers; Antonio Salvador; Manuel Portolés; Vicente Bertomeu; Miguel Rivera Journal: PLoS One Date: 2012-02-23 Impact factor: 3.240
Authors: Estefanía Tarazón; Esther Roselló-Lletí; Miguel Rivera; Ana Ortega; Maria Micaela Molina-Navarro; Juan Carlos Triviño; Francisca Lago; José Ramón González-Juanatey; Placido Orosa; José Anastasio Montero; Antonio Salvador; Manuel Portolés Journal: PLoS One Date: 2014-03-05 Impact factor: 3.240
Authors: Zachary I Whinnett; S M Afzal Sohaib; Siana Jones; Andreas Kyriacou; Katherine March; Emma Coady; Jamil Mayet; Alun D Hughes; Michael Frenneaux; Darrel P Francis Journal: BMC Cardiovasc Disord Date: 2014-04-03 Impact factor: 2.298